LONG-TERM anticoagulant therapy is being used frequently in the management of certain vascular and thromboembolic diseases. Results predominantly favorable in respect to prolonged survival and decreased morbidity have been reported from use of coumarin anticoagulants in these diseases. [1] [2] [3] [4] However, there has not been adequate evaluation of the ease or difficulty with which a satisfactory and practical program of prolonged anticoagulant therapy can be carried out. The purpose of this paper is to evaluate this aspect of anticoagulant therapy in ambulatory patients with vascular and thromboembolic diseases who have been observed during the past 101½2 years.
The following specific problems were considered: (1) the adequacy of control of prothrombin activity, (2) the hemorrhagic complicatious occurring during treatment, (3) the vascular and thromboembolic complications occurring during treatment, (4) the reasons for discontinuing treatment, (5) the vascular and thromboembolic complications that occurred immediately following cessation of treatment, and (6) the problems occasioned by surgery in patients on treatment.
Material and Methods

Selection of Patients
Accepted for study were the cases of patients who had received anticoagulant therapy continuously for 2 months or longer while residing in Rochester, Minnesota, and vicinity. The period of the study extended from July 1949 through December 1959. All of the patients had some From the Mayo Clinic and the Mayo Foundation, Rochester, Minnesota.
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Circulation, Volume XXV, February 1962 form of occlusive vascular or thromboembolic disease. Myocardial infarction (43 per cent of cases) and cerebral vascular insufficiency (31 per cent) with or without infaretion were the two most common indications for long-term anticoagulant therapy (table 1) . All of these patients were under the continuous care of physicians of a single section* of the Mayo Clinic and were followed as outpatients during the period of treatment with long-term anticoagulants. The physicians were specialists in internal medicine and were experienced in the use of anticoagulant therapy. All except six patients were started on anticoagulants during hospitalization for acute complications of their underlying vascular or thromboembolic disease. Of necessity, all patients, or the relatives and friends caring for them, were considered cooperative and of sufficient intelligence to follow the program outlined.
The 139 separate periods of long-term anticoagulant therapy of more than 2 months each involved 126 patients. Nine men and two women had two separate periods of treatment, and one man had three separate periods of treatment. For purposes of presentation, 139 will be used as the number of cases in the studv. Procedure Bishydroxycoumarin (Dicumarol) was the anticoagulant used in all cases. A modified Ouiek one-stage prothrombin test5 was used in our laboratories to measure the prothrombin activitv. Determinations of prothrombin activity were made every 3 to 5 days during 1949 and 1950; since that time the interval has been extended to as much as 1 month in some cases but has averaged approximately 14 days. On the days that the prothrombin determinations were made the patients were advised of the result (usually by telephone), and the dose schedule of bishydroxycoumarin was prescribed for the subsequent interval. An effort was made by the physician to keep the prothrorn- bin activity within the therapeutic range-that is, between 10 and 30 per cent of normal, the range generally accepted as effective and safe.6
The required dosage of bishydroxycoumarin varied from patient to patient and from time to time in the same patient without apparent reason. For the majority of patients the dosage ranged from 25 to 125 mg. per day.
Technics for Specific Problems
In estimating adequacy of control of the anticoagulant treatment in each patient, the pereentage of prothromibin values within the therapeutic range was used to calculate the per cent of the time each patient's prothrombin activity was kept in the therapeutic range. Thus, if three of four prothrombin determinations were within this range, the patient was described as being satisfactorilyv controlled 75 per cent of the tinme. Also, in estimating the adequacy of control for this study, exelnision was made of prothrombin determinations obtained during the first 2 months of therapy and those obtained within 2 weeks before and 2 weeks a fter any surgical procedure. These exclusions seemed justified because the periods were adjustment periods and not representative of the longrange aspects of the problem.
In considering the hemorrhagic complications that occurred in patients receiving anticoagulant therapy, the effect of hypertension was studied. Hypertension was arbitrarily said to be present if more than half the blood pressure readings recorded during the period of anticoagulation and the 6 months prior to the period of anticoagulation exceeded 175 mm. of mercury systolic or 100 diastolic.
In order to assess whether vascular and thromboembolie complications occurred when long-term anticoagulant therapy was discontinued, the course POLLARD ET AL. of patients who stopped treatment was studied. The 2-month period after discontinuation was selected arbitrarily as the critical period of followup study because it seemed that if complications related to the discontinuance of anticoagulant therapy were to occur, they should occur within this period.
Findings Among the 139 cases that comprised the group studied, the patients were men in 91 and women in 48. The average age was 59.4 years, with a range of 22 to 84 years. Most of the patients were in the fifth, sixth, and seventh decades of life; and only four persons were less than 40 years of age. The months of treatment averaged 18.3 and ranged from 3 to 69 months. Sixty-one patients were still receiving treatment at the conclusion of the study. Prothrombin times were obtained an average of 2.6 times per month per case. Hypertension was present in 27 (20 per cent of cases.
Effectiveness of Control
In 79 cases (57 per ceiit) the prothrombin' activity was within the therapeutic range at least 80 per cent of the time (table 2) . Two separate groupings have been tabulated because late in 1956, following a review of success in maintaining patients within the therapeutic range, a more diligent effort was made to improve the control. This diligence raised from 49 to 66 the percentage of cases with prothrombin activities in the therapeutic range more than 80 per cent of the time; but even with such increased effort, in one third of the cases the desired range was not maintained as much as 80 per cent of the period of treatment.
Hemorrhagic Complications
In 47 of the 139 cases (34 per cent) there were 61 hemorrhagic complications (table 3) . Some of these episodes-diagnosed as epistaxis, ecchymosis, and postmenopausal bleeding-might have occurred whether or not the patient was receiving anticoagulants. However, in listing hemorrhagic complications it; seemed necessary to include all bleeding that the physician considered significant enough to note in the record.
Sixty-nine per cent of these bleeding epi-Circulation, Volume XXV, February 1962 1957, were counted in both subperiods but only sodes occurred while the prothrombin activity of the patient was within the therapeutic range; 20 per cent occurred while the prothrombin activity was depressed below the therapeutic range (less than 10 per cent of normal); and 11 per cent occurred while the prothrombin activity was between normal and the therapeutic range (between 30 and 100 per cent of normal). The average age of the patients who had hemorrhagic complications was 62.4 years. Included among the 61 hemorrhagic complications were 15 bleeding episodes that caused major incapacity or were dangerous to life-and indeed resulted in three deaths (table 4) . These 15 major hemorrhagic complications occurred in 14 (10 per cent) of the 139 cases as here defined and involved 14 patients. All but one of those patients with major bleeding had prothrombin activity greater than 10 per cent of normal at the time of the complication. The average patient age in the 15 cases with major bleeding episodes was 66.7 years.
Hypertension was more common among the patients who had these hemorrhagic complications. Fourteen (30 per cent) of the 47 patients who had hemorrhagic complications and six (43 per cent) of the 14 patients who had major bleeding episodes had hypertension. As noted previously, significant elevation of blood pressure was found in only 20 per cent of the total 139 cases.
The cases with hemorrhagic complications did not differ markedly from the whole group cerebral infaretioni. In the sixth case sudden death was attributed to acute coronary insufficiency, but necropsy was not done. Eleven (53 per cent) of the 21 patients in this group were within the tlherapeutic range more than 80 per cent of the time. The average age of the group was 58.9 years. Of special interest was the fact that nine of the 21 had also experienced bleeding complications during the period of their treatment with anticoagulants. Eighteen of the 23 vascular or thromboembolic episodes occurred when the patient's prothrombin activity was within the thera-peutic range. The other five occurred when the prothrombin activity was between normal and the therapeutic range, that is, 30 to 100 per cent of normal.
Reasons for Discontinuing Treatment
In 78 (56 per cent) of the 139 cases, anticoagulant therapy was stopped during the period of study. Medical judgment-the decision of the physician that the period of treatnient had been adequate-was the most frequent reason for discontinuing anticoagulant treatment. Other reasons for stopping therapv are listed in table 5. Social problems such as vacations, uncooperativeness, and expense. were the reasons for discontinuing anticoagulants in 22 cases. Thus in 16 per cent of the 139 instances the patients did not continue prolonged anticoagulant therapy although the indications for its use were still presenit.
Recurrence of Vascular or Thromboembolic Episodes after Stopping Therapy
Eleven (17 per cent) of the 64 patients who stopped anticoagulant therapy and who could be followed had thromboembolie or vascular episodes reappearing within 2 months. Myocardial infaretion and cerebrovascular insufficiency with or without cerebral infaretion occurred most commonly (table 6). Three of 
Surgery in Patients Receiving Therapy
Twenty patients had 30 surgical procedures while on long-term anticoagulant therapy (table 7) . Eleven patients had 14 dental extractions, seven patients had eight minor surgical procedures, and six patients had eight major operations.
The minor surgical (including dental) procedures were done with the patients' prothrombin activities ranging from 18 to 100 per cent of normal. Three of the 14 dental extractions were performed when the patients' prothrombin activities were in the therapeutic range. During major procedures the prothrombin activities in all cases were near normal. Excessive bleeding did not occur in any case.
The only complication of surgery in any of these patients was a nonfatal cerebral infaretion following dental extraction in a 57-yearold man whose prothrombin activity had been brought to normal for this procedure.
Discussion
An attempt has been made to assess the ease or difficulty with which a satisfactory and practical program of prolonged anticoagulant therapy can be carried out. Because no Circulation, Volume XXV, February 1962 untreated control group was available, no effort has been made to assess the effect of anticoagulant therapy on the course or prognosis of the underlying vascular or thromboembolic disease. Without an adequate control group we think conclusions as to the effectiveness of coumarin therapy cannot be made.
It was disquieting to find that with a conscientious effort, a familiar drug, and the services of a reliable laboratory, the prothrombin activity was maintained within the therapeutic range more than 80 per cent of the time in only 57 per cent of the cases. After 1957, knowledge of the previously less thani desirable results stimulated an effort that brought this figure to 66 per cent. If it is necessary for prothrombin activity to remain within the range of 10 to 30 per cent of normal in order to influence favorably vascular and thromboembolic disease, our data suggest that an even greater effort must be made. This raises the problem of feasibility and practicality, for the regimen outlined in this paper represents considerable investment of the patient's time and money and requires continual supervision by the physician.
Another interesting observation was the number of hemorrhagic complications that occurred in this group of patients while receiving anticoagulant treatment. The data suggest that older patients and those with hyperten- *The single complication of a hemorrhagic or thromboembolic type was cerebral thrombosis in a patient whose prothrombin activity had been brought to 100 per cent for the extraction. sion were m-ore often affected by hemorrhagic complications. If this is true, then probably younger patients and those without hypertension can undergo anticoagulant therapy with more safety. The majority of the hemorrhagic complications as well as the majority of vascular and thromboembolic episodes occurred while the patients' prothrombin activities were in the desired therapeutic range. This experience suggests that the prothrombin activity as determined by our technic is not an entirely adequate measurement of the patients' bleeding or thrombosing propensities while receiving long-term coumarin anticoagulant therapy. It indicates further that with the present therapeutic methods a substantial number of hemorrhagic complications and a significant number of vascular and thromboembolic episodes are inevitable.
A rather high rate of vascular and thromboembolic episodes was noted after discontinuation of anticoagulant therapy. This may represent a rebound or overshoot phenomenon of the clotting mechanism. It may reflect only the natural course of the underlying disease, however, which reasserts itself once the restraining therapy is discontinued. At any rate, the 17 per cent incidence of these complications after discontinuation of anticoagulant treatment is high enough to emphasize the possible danger of stopping therapy once it has been undertaken. The additional fact that 16 per cent of the patients who began receiving therapy discontinued it while the indication for treatment was still present adds significance to this figure. Here, then, is another consideration the physician must weigh when contrasting the gravity of the disease to be treated against the calculated risk of long-term anticoagulant therapy.
Summary and Conclusions
In 139 cases, 126 patients having ocelusive vascular disease were treated with bishydroxycoumarin (Dicumarol) for periods varying from 3 to 69 months, with a mean duration of 18.3 months. Of particular concern were the problems and limitations that confront the physician managing long-term anticoagulant therapy.
Fifty-seven per cent of these patients had Circulation, Volume XXV, February 1962 prothrombin times in the therapeutic range during more than 80 per cent of the time they were under treatment (adjustment periods excluded). One third of the cases were marked by hemorrhagic complications, which included major bleeding complications in 10 per cent of the total. The incidence of bleeding complications, and especially the major bleeding complications, was associated with either an increased incidence of arterial hypertension or increased age. Three patients died as a result of a hemorrhagic complication that occurred during long-term anticoagulant therapy. Sixty-nine per cent of the bleeding episodes occurred when the prothrombin activity was within the therapeutic range (10 to 30 per cent of normal).
Sixteen per cent of the patients discontinued anticoagulant therapy although the indications for its use were still present. Eleven (17 per cent) of the 64 patients who stopped anticoagulant therapy and could be traced had recurrent vascular or thromboembolic episodes within 2 months. Three of these 11 patients died.
Surgery was performed in 20 cases during long-term anticoagulant therapy. The patienlts' prothrombin activities were at various levels, though for major operations all were near normal. The only complication was a minor cerebral infaretion in a patient whose prothrombin activity had been brought to normal for surgery.
In view of the limitations in the practical management of patients on long-term anticoagulant therapy, plus the inconvenience, expense, and risks involved, the physician is compelled to appraise carefully the indications for such treatment in each patient before undertaking its use.
